The Philadelphia chromosome-positive (Ph+) leukemias, including chronic myeloid leukemia (CML) and Ph+ B- cell acute lymphoblastic leukemia (B-ALL), are prevalent blood cancers for which our current therapies are inadequate. While BCR-ABL1 tyrosine kinase inhibitors (TKIs) such as imatinib mesylate have replaced hematopoietic stem cell transplantation (HSCT) as initial therapy for CML, complete molecular remissions are rare and acquired resistance to TKI therapy is a significant clinical problem. Eligible Ph+ B-ALL patients undergo allogeneic HSCT in first remission following chemotherapy, but over half will relapse. Hence, it is likely that current therapy will not cure most Ph+ leukemia patients, and effective methods to eradicate residual leukemia are needed. To accomplish these goals, well-characterized mouse models of CML and B-ALL will be utilized to determine the mechanisms of pathogenesis of these diseases, to identify signaling pathways critical to leukemogenesis and to the genesis of leukemia-initiating or leukemia stem cels, and finally to validate these pathways as targets for therapy and conduct preclinical testing of molecularly targeted drugs. Together, these studies should yield important new knowledge that will improve the effectiveness of our current treatments for Ph+ leukemia, and increase the proportion of patients that are cured of their disease.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-BMCT-C (09))
Program Officer
Mufson, R Allan
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Irvine
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Gu, S; Sayad, A; Chan, G et al. (2018) SHP2 is required for BCR-ABL1-induced hematologic neoplasia. Leukemia 32:203-213
Cortes, Jorge; Talpaz, Moshe; Smith, Hedy P et al. (2017) Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica 102:519-528
Hu, Yeguang; Zhang, Zhihong; Kashiwagi, Mariko et al. (2016) Superenhancer reprogramming drives a B-cell-epithelial transition and high-risk leukemia. Genes Dev 30:1971-90
Jena, N; Sheng, J; Hu, J K et al. (2016) CDK6-mediated repression of CD25 is required for induction and maintenance of Notch1-induced T-cell acute lymphoblastic leukemia. Leukemia 30:1033-43
Gu, Shengqing; Chan, Wayne W; Mohi, Golam et al. (2016) Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. Blood 127:1803-13
Mughal, Tariq I; Barbui, Tiziano; Abdel-Wahab, Omar et al. (2015) Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. Leuk Lymphoma 56:1938-48
Joshi, Ila; Yoshida, Toshimi; Jena, Nilamani et al. (2014) Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia. Nat Immunol 15:294-304
Mughal, Tariq I; Girnius, Saulius; Rosen, Steven T et al. (2014) Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leuk Lymphoma 55:1968-79
Hsieh, Mo-Ying; Van Etten, Richard A (2014) IKK-dependent activation of NF-?B contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1. Blood 123:2401-11
Krause, Daniela S; Lazarides, Katherine; Lewis, Juliana B et al. (2014) Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche. Blood 123:1361-71

Showing the most recent 10 out of 40 publications